Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P015 (Convalife Pharma)
- Development stage
- Unknown
- Lead developer
- Convalife Pharmaceutical
- Modality
- Small Molecules
01
Overview
P015 (Convalife Pharma): sourced facts only. name: "Enzymatic assay results demonstrated that P015 exhibited potent inhibitory activity against both PARP7 and PARP12, with IC50 values below 10 nM for both enzymes." [DOI:10.1158/1538-7445.am2026-5119]; target: "Enzymatic assay results demonstrated that P015 exhibited potent inhibitory activity against both PARP7 and PARP12, with IC50 values below 10 nM for both enzymes." [DOI:10.1158/1538-7445.am2026-5119]; developer: "Convalife Pharmaceuticals, Shanghai, China." [DOI:10.1158/1538-7445.am2026-5119]; modality: "We have identified and preliminarily characterized P015, a small-molecule inhibitor with sub-10 nM IC50 values against PARP7&12 at the enzymatic level." [DOI:10.1158/1538-7445.am2026-5119]
Beyond the preview
Go deeper on P015 (Convalife Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P015 (Convalife Pharma).